Last year, these treatments accounted for 75% of the $236B in annual sales set to vanish with the loss of exclusivity.

Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients Prepa ...

Safety: ARV-102 was generally well tolerated at single doses up to 200 mg and multiple daily doses up to 80 mg, with no discontinuations due to adverse events (AEs) or serious adverse events (SAEs) ...

Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients ...

U.S. President Donald Trump's embrace of an old generic drug called leucovorin for use against a rare disorder that causes ...

Cantor Fitzgerald’s new price target on CABA represents over 1,000% potential upside to the stock’s closing price on Thursday ...

Shanghai Zhimeng Biopharma Inc. ( "Zhimeng") announced that its self-developed new-generation potassium channel ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational therapy being ...

“IBSRELA continues to outperform and is the foundation of our portfolio and the main engine for Ardelyx's future growth,” CEO ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ...

A research team has developed a new chemotherapeutic agent, LiPyDau, which shows remarkable efficacy against multiple tumor ...